(Sr.) Medical Science Liaison, Hematology (West)

Company: 0750 Stemline Therapeutics Inc

Contract Type:

Join us in shaping the future of Menarini - with passion, integrity, and a deep commitment to people.

About Menarini Group - Menarini is a leading international biopharmaceutical company committed to advancing health through innovation, research, and quality. For more than 135 years, we have worked to improve patients’ lives across a broad range of therapeutic areas through our dedication to science, integrity, and care for people. With a strong foundation in scientific excellence and a purpose-driven culture, Menarini offers diverse career opportunities for professionals eager to make a meaningful impact on global health.

Opportunity

Menarini Stemline is hiring a (Sr) Medical Science Liaison. The Medical Science Liaison (MSL) will be responsible for the scientific exchange of Stemline’s pipeline, disease state awareness and general scientific discussions of data with Key Opinion Leaders (KOLs) and Health Care Providers (HCPs). The MSL will represent Stemline in the support of research interest with both Company Sponsored Trials and Investigator Initiated Research. MSLs provide medical information through scientific exchange in a fair and balanced manner and provide clinical/scientific support. The MSL will also support the safety education to HCPs and allied health professionals for the use of Stemline products in in approved indications.

Territory includes:

• California

• Oregon

• Washington

• Nevada

• Idaho

• Alaska

• Hawaii

Responsibilities

• Identify key thought leaders and establish, foster, cultivate, and maintain relationships with healthcare providers (HCPs) in academic and community centers within assigned territory including but not limited to clinical investigators, national and regional opinion leaders and speakers.
• Develop and execute territory plans in alignment with US and global Medical Affairs strategies.
• Provide insights/feedback on emerging scientific/clinical data that enhance the value and appropriate use of Stemline products as part of compliant collaboration with internal stakeholders.
• Gives medical/scientific presentations to internal and external groups.
• Present appropriate clinical and scientific information to healthcare providers in response to unsolicited requests (as appropriate) in a fair and balanced manner.
• Liaise with academic research institutions to address medical and scientific inquiries, facilitate investigator-initiated clinical trials and support company-sponsored clinical trials. Assists in the development of medical communications materials and publications.
• Act as the primary point of contact and facilitator for all aspects of investigator-sponsored trials (ISTs), from submission, review, and approval, through study activation/completion.
• In collaboration with medical and clinical operations teams, support Stemline-sponsored trials through trial site recommendations and raise awareness of the trials and accrual timelines.
• Serve as a scientific resource to commercial partners, as appropriate, to support activities.
• Support the execution, organization, and planning of advisory boards.
• Professionally represent Stemline at select medical and scientific conferences and meetings.
• Sustains expertise in therapeutic area treatment management and new therapies, competitive products, and features, and provide feedback to the senior leadership team on specific initiatives.
• Provides supervision, administrative support and coaching to peers.

Skills/Knowledge

• Degree is required; Advanced degree preferred: (MD, PhD, PharmD)
• At least 5 years of MSL experience preferred.
• At least 2 years MSL/Medical Affairs experience in Hematology & Oncology; Hematology focus preferredMalignant hematology experience preferred
• Strong knowledge and/or experience of healthcare and access environments
• Proven ability to work independently, as well as cross-functionally with numerous internal stakeholders in a high-matrixed environment, including joint venture collaborations
• Preferred experience on product launches or demonstrated success as product or therapeutic point of contact
• Excellent interpersonal communication and presentation skills, strong personal integrity, teamwork abilities, and a customer focus are necessary
• Must be able to organize, prioritize, and work effectively in a constantly changing environment
• Strong compliance knowledge and adherence to corporate compliance policies
• Current working knowledge of FDA, OIG, ICH, GCP, PhRMA Code, HIPAA and other compliance regulations and guidelines relevant to industry interactions with healthcare professionals
• Demonstrated technical acumen including MS Office skills, ability to adopt and leverage multiple business applications
• This position will require greater than 70% domestic travel, including within the territory, and to the home office and national meetings

Base Salary Range of $208,000 - $245,000. Menarini Stemline offers generous compensation and benefits packages, including Short and Long-Term Incentive Programs, Fidelity 401(k) (with company match of 6%), PPO and HDHP insurance plans, Company paid Basic Life & AD&D insurance and pre-tax FSA/HSA programs.

Menarini Stemline is committed to creating an inclusive environment for all employees. All qualified applicants will receive consideration for employment without regard to race, color, religion, sex, sexual orientation, gender identity, national origin, disability, or status as a protected veteran.

#LI-Remote

Base Salary Range of:

Menarini Stemline offers generous compensation and benefits packages, including Fidelity 401(k) (with company match), Healthcare insurance, Company-paid Basic Life & AD&D insurance and pre-tax FSA/HSA programs.

Menarini Stemline is committed to creating an inclusive environment for all employees. All qualified applicants will receive consideration for employment without regard to race, color, religion, sex, sexual orientation, gender identity, national origin, disability, or status as a protected veteran. Reasonable accommodations may be made to enable qualified individuals with disabilities to perform the essential functions.

The Company

Founded in 1886 in Naples under the name of Farmacia Internazionale, Menarini moved in 1915 to Florence where the Group’s headquarters are still located today. High quality therapeutics and diagnostics solutions for patients, ethics as our underlying principle, dedication to innovation and advancement, strong people centricity and environmental sustainability. These five pillars form the foundation of the Menarini Group, an Italian pharmaceutical company with nearly 135 years of history.

The Menarini Group is present in 70 countries and our products are sold in 140 locations around the world. Its companies span from Europe to Asia, to Africa and the Middle East, to Central America and to the United States where with the acquisition of Stemline Therapeutics, a NASDAQ-listed biopharmaceutical company, the company marked its entry into the US oncology market.

Thanks to the valuable contribution of around 18,000 employees, every year more than 500 million packs of drugs are produced at the Group's 18 manufacturing sites including a biotech plant for the manufacturing of monoclonal antibodies that also serves external clients distributed across 6 continents.

Menarini has made a strong commitment to oncology, investing in a pipeline of five investigational compounds for the treatment of a variety of haematological and solid tumours. The acquisition of Stemline Therapeutics in June 2020, further strengthened Menarini’s oncology portfolio, adding both commercial and clinical-stage assets. Tagraxofusp is a novel, first in class targeted therapy for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN) and to date, the only approved treatment for BPDCN in the U.S. and EU, and the first and only approved CD123-targeted therapy. Tagraxofusp is also being evaluated as both a single agent and in combination, in other CD123+ indications, including acute myeloid leukaemia (AML), chronic myelomonocytic leukaemia (CMML), and myelofibrosis (MF).

Additionally, Menarini received exclusive rights to commercialise Selinexor for the treatment of oncology indications in the European Union and other European countries (including the United Kingdom), Latin America and other key countries. Menarini has signed an exclusive licensing agreement with Karyopharm Therapeutics for the rights to commercialise an innovative therapeutic option in Europe, Latin America, Turkey, Russia, and CIS countries. Selinexor is a first-in-class, oral Selective Inhibitor of Nuclear export compound for the treatment of hematologic cancers and solid tumours. It is already marketed in the US for multiple myeloma and is under development for solid tumour indications. Selinexor is registered in the EU for both early and late lines.

Menarini entered into a global licence agreement with Radius Health to complete the development of Elacestrant, an oral SERD in late-stage Phase 3 development for hormone receptor-positive advanced breast cancer. Following a successful phase 3 study, Menarini Stemline received FDA approval in January 2023 under priority review and successfully oversaw a strong launch in February to the US market with the EMA review process concluded positively in September 2023.

Menarini’s commitment to oncology is also reflected in the investments made in the liquid biopsy diagnostic field through its affiliate Menarini Silicon Biosystems (MSB), a pioneer in rare cell analysis and non-invasive, advanced diagnostic solutions. MSB’s CELLSEARCH Circulating Tumour Cell (CTC) Test is the first and only clinically validated blood test cleared by the U.S. Food & Drug Administration (FDA) for detecting and counting CTCs in metastatic breast, prostate, and colorectal cancer when used in conjunction with other clinical monitoring methods.

Since 2021, MSB has offered in the US a menu of non-invasive Laboratory Developed Tests (LDTs) provided through its CLIA/CAP accredited US-based Lab. The services include CMC enumeration, CTC enumeration and PDL-1/HER2 biomarker and offer a minimally invasive approach to follow cancer patient’s therapeutic journey.

In 2022, the company launched the CELLSEARCH® Circulating Multiple Myeloma Cell (CMMC) Enumeration LDT, the first-of-its-kind, which directly measures levels of plasma cells in the blood of patients. This test provides new, complementary information to that of the bone marrow biopsy and other standard-of-care measures. Due to its minimally invasive nature, it can be performed serially to assess plasma cell burden without requiring repeated bone marrow biopsies.

Menarini's vision and uniqueness in oncology is to bring together innovative therapeutic solutions and advanced liquid biopsy-based diagnostics for faster, more effective and precise patient management.

It is an exciting time in the company’s development and an excellent opportunity for individuals joining us to contribute to building and shaping Menarini Stemline's Oncology business.

For more details on how we handle your data, please refer to our Privacy Policy .